Aspen Neuroscience published peer-reviewed preclinical data in Cell Stem Cell on Sasineprocel (ANPD001), an autologous iPSC-derived dopamine neuron replacement therapy for Parkinson's disease, reporting improved motor function in disease models and no treatment-related adverse findings in a nine-month GLP rodent safety study. The paper also describes NeuriTest, a machine learning–based RNA sequencing assay used to verify the molecular identity and predicted performance of each patient-specific cell product. Because the cells are derived from the patient's own skin biopsy, the single-dose therapy is intended to restore lost dopaminergic neurons without immunosuppression.
Key Points
- Autologous iPSC-derived dopamine neurons improved motor function in preclinical models
- Nine-month GLP rodent study showed no treatment-related adverse findings
- RNA sequencing assay verifies identity of each patient-specific product
Longevity Analysis
Neurodegeneration has largely been managed by compensating for lost signaling rather than restoring the cells that generate it; replacing dopaminergic neurons with a patient's own reprogrammed cells shifts the target from symptom control to structural repair. Using the recipient's own genome removes the need for lifelong immune suppression, avoiding a chronic trade-off that itself accelerates vulnerability to infection and malignancy. The accompanying sequencing-based release assay addresses the central problem of personalized regenerative products — confirming that what is manufactured for each individual actually behaves as intended before it is delivered.
Original published by LT Wire.